Ocuphire Pharma Investor Update

RM 24 Maximum Pupil Dilation Results in Loss of Near Vision Nyxol Returns Near Vision to Baseline Levels Statistically Faster Compared to Placebo Change from Baseline (Letters Read) 2 -2 -6 -8 Mydriatic -10 -1 Baseline Near Vision Max dilation; Treatment 0 p=0.0002 MIRA-3 Phase 3 Trial DCNVA Letters Read Study Eye (mITT) p=0.009 1.5 1 2 Time Post-Treatment with Nyxol/Placebo MIRA-3 Table 14.3.6.1.1 (Safety Population) (mITT). DCNVA- Distance-Corrected Near Visual Acuity. 3 4 -Nyxol (n=244) Placebo (n=124) 5 p=0.03 6 Ocuphire PHARMA

View entire presentation